Systematic conversion to generic tacrolimus in stable kidney transplant recipients

Clinical Kidney Journal

Volumn 7, Issue 2, 2014, Pages 151-155

  Rosenborg, Staffan ^a   Nordström, Annica ^a   Almquist, Tora ^a   Wennberg, Lars ^b   Bárány, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

drugs; generic; kidney transplantation; quality assurance project; tacrolimus

Indexed keywords

CREATININE; GENERIC DRUG; TACROLIMUS; TACROLIMUS SANDOZ; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG COST; DRUG MONITORING; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

EID: 84897447512     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu015     Document Type: Article

References (14)

1. Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int. 2010; 115: S1-S7
2. Klintmalm GB. Immunosuppression, generic drugs and the FDA. Am J Transplant 2011; 11: 1765-1766
3. Summary of Product Characteristics: Prograf. http://www. fass. se (4 March 2013, date last accessed)
4. Guideline on the Investigation of Bioequivalance. http://www. ema. europa. eu/docs/en-GB/document-library/Scientific-guide line/2010/01/ WC500070039. pdf (27 January 2014, date last accessed)
5. Noceti OM, López C, Lagomarsino G et al. Impact of switching Prograf astellas pharma to tacrolimus servimedic in liver transplant recipients in Uruguay. Ther Drug Monit 2011; 33 (P246):545
6. Momper JD, Ridenour TA, Schonder KS et al. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 2011; 11: 1861-1867
7. Spence MM, Nguyen LM, Hui RL et al. Evaluation of clinical and safety outcomes associated with conversion from brandname to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy 2012; 32: 981-987
8. McDevitt-Potter LM, Sadaka B, Tichy EM et al. A multicenter experience with generic tacrolimus conversion. Transplantation 2011; 92: 653-657
9. Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 1999; 31 (7A):21S-24S
10. Alloway RR, Sadaka B, Trofe-Clark J et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 2012; 12: 2825-2831
11. Prescribed and Dispensed Drugs in Sweden. Stockholm, Sweden: Apotekens Service AB
12. Drug Sales in Sweden-Analysis and Prognosis: May 2012. Stockholm, Sweden: National Board of Health and Welfare, 2012
13. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
14. Connor A, Prowse A, MacPhee I et al. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. Transplantation 2012; 93: e45-e46